Moleculin Biotech Insider Buying Boosts Confidence Ahead of Annamycin’s 2026 Hema Conference Debut
Insider buying by Moleculin Biotech’s CSO signals confidence as Annamycin gains clinical traction, boosting investor interest and potential NDA upside.
3 minutes to read